Summary of healthcare resource use in home-based and centre-based cardiac rehabilitation by months of follow-up
| Trial Author (year) | Dalal et al (2007) | Gordon et al (2002) | Bell (1998) | Carlson et al (2000) | Marchionni et al (2003) | Jolly et al (2007) | Moholdt et al (2012) | Oerkild et al (2011) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Follow-up | 9 months | 3 months | 0–6 months | 6–12 months | 6 months | 14 months | 12 months | 24 months | 6 months | 12 months |
| Rehospitalisations | Not reported | Number and length of admissions same between groups | ||||||||
| N patient (%) | Home 9/60 (15%) | Home 21/90 (23%) | 13/89 (15%) | |||||||
| Centre 6/44 (14%) | Centre 19/88 (22%) | 12/84 (14%) | ||||||||
| p=0.845 | p=0.78# | p=0.95# | ||||||||
| Mean (SD) | Home 2.2 (0.9)† | Home 0.46 (SE 0.1) | Home 0.08 (0.34) | Home 0.20 (0.45) | ||||||
| Centre 1.2 (0.6) | Centre 0.33 (SE 0.1) | Centre 0.12 (0.41) | Centre 0.26 (0.57) | |||||||
| p=0.383 | p=0.49 | p=0.3 | p=0.3 | |||||||
| Primary care consultations | Not reported | Not reported | ||||||||
| Mean (SD) | Home 6.3 (0.6) | Home 6.6 (3.6)* | 5.4 (4.1) | Home 0.65 (1.14) | Home 0.53 (1.14) | |||||
| Centre 7.0 (0.9) | Centre 6.6 (4.1) | 4.6 (3.7) | Centre 0.72 (1.54) | Centre 0.66 (1.42) | ||||||
| p=0.514 | p=1.00# | p=0.19# | p=0.8 | p=0.7 | ||||||
| Secondary prevention medication | Not reported | |||||||||
| N patients (%) Beta-blockers | Home 31/49 (63%) | Home 36/97 (37%) | Home 19/38 | Home 169 (72.2%) | Home 161 (71.6%) | Home: 8/14 (57%) | ||||
| Centre 24/34 (71%) | Centre 17/45 (38%) | Centre 18/42 | Centre 171 (73.4%) | Centre 164 (72.2%) | Centre: 15/16 (94%) | |||||
| p=0.49 | NS | p=0.52# | p=0.8 | p=0.9 | p=0.02* | |||||
| ACE inhibitors | Home 30/49 (61%) | Home 25/97 (26%) | Home 4/38 | Home 176 (75.2%)* | Home 177 (78.7%)* | Home: 1/14 (7%) | ||||
| Centre 24/33 (73%) | Centre 8/45 (18%) | Centre 4/42 | Centre 161 (69.1%)* | Centre 156 (68.7%)* | Centre: 0/16 (0%) | |||||
| p=0.28 | NS | p=0.88# | p=0.1 | p=0.02 | p=0.28* | |||||
| Statins | Home 48/49 (98%)* | Home 73/97 (75%) | Home 5/38 | Home 216 (92.3%)** | Home 195 (86.7%)** | Home: 6/14 (43%) | ||||
| Centre 30/35 (88%)* | Centre 33/45 (73%) | Centre 8/42 | Centre 221 (94.8%)** | Centre 206 (90.7%)** | Centre: 2/16 (13%) | |||||
| p=0.18 | NS | p=0.47# | p=0.3 | p=0.2 | p=0.07* | |||||
| Antiplatelets | Home 46/49 (94%) | Home 94/97 (97%)* | Home 15/38 | Home 227 (97.0%)† | Home 214 (95.1%)† | Home: 14/14 (100%) | ||||
| Centre 30/35 (86%) | Centre 45/45 (100%)* | Centre 20/42 | Centre 226 (97.0%)† | Centre 220 (96.9%)† | Centre: 14/16 (100%) | |||||
| p=0.21 | NS | p=0.54# | p=1.0 | p=0.3 | p=0.18* | |||||
| Comments | †number of nights *lipid lowering drugs | *antiplatelets & anticoagulants NS: not statistically significant | *GP consultations | #P-value calculated by authors of the present report | SE: standard error | *angiotensin-converting-enzyme inhibitor or Angiotensin II receptor antagonist **cholesterol-lowering drugs †Aspirin or antiplatelet drugs | *angiotensin-converting-enzyme inhibitor or Angiotensin II receptor antagonist **cholesterol-lowering drugs †Aspirin or antiplatelet drugs | *p Value calculated by authors of the present report. | ||
Figures are means (SD or 95% CI).
GP, general practitioner; NS, not statistically significant; SD, standard deviation.